Predictive Kits for Chemoresistance
This technology will be packaged into two novel diagnostic kits introduced under the trade names SETAX™ and SEPEX™ to the market. We will offer all the required materials, including clear and concise instructions, allowing for feasible clinical utilization of SETAX™ and SEPEX™ in standard pathology laboratories. These tests will provide invaluable information for treatment decision making by identifying patients who will or will not benefit from standard chemotherapy with platinum drugs. The technology will also be offered as a service during the FDA clearance process for SETAX™ and SEPEX™.